Ye Weiguo, serving as the Chief Operating Officer for GYRE Therapeutics, Inc. (NASDAQ:GYRE), has completed the sale of 34,976 shares of common stock. According to a recent Form 4 filing, the transaction spanned two days, June 4 and June 5, 2026, generating total proceeds of approximately $218,561. The insider activity unfolds as the company manages post-merger integration following a major acquisition and advances regulatory submissions for its pipeline assets.
The liquidation of shares occurred across multiple transactions over the two-day period. On June 4, Mr. Ye sold 19,575 shares at a weighted average price of $6.13 per share. These specific transactions were executed at prices ranging from $6.05 to $6.30. The following day, June 5, the executive sold an additional 15,401 shares. This second tranche was sold at a weighted average price of $6.40 per share, with individual transaction prices varying between $6.15 and $6.60. The filing confirms that all shares were sold through direct ownership.
Concurrent with the sales, Mr. Ye exercised stock options to acquire an equivalent number of shares, totaling 34,976. The total cost to acquire these shares was $26,232, calculated at an exercise price of $0.75 per share. The option exercises were allocated similarly to the sales, with 19,575 shares exercised on June 4 and 15,401 shares on June 5. The options involved were fully vested and carry an expiration date of October 31, 2030.
These insider transactions occur as GYRE stock experiences notable volatility. Shares have gained approximately 8% over the past week. Analysis from InvestingPro indicates the stock currently appears overvalued relative to its Fair Value. The company carries a beta of 4.92, a metric indicating substantial price swings relative to the broader market. GYRE shares closed at $6.05, reflecting a decline of $0.24 or 3.82% from the previous close. After-hours trading showed a price of $6.05 at 16:10:04.
Corporate developments have been prominent for GYRE recently. The company announced the completion of its acquisition of Cullgen Inc., a clinical-stage biopharmaceutical company. This all-stock transaction is valued at approximately $300 million, resulting in Cullgen becoming a wholly owned subsidiary of Gyre. Following the acquisition, Dr. Ying Luo, formerly the CEO of Cullgen, has assumed the roles of President and CEO of Gyre and joined its Board of Directors. Ping Zhang continues to serve as Chairman of the Board.
Regulatory advancements also accompany these corporate changes. Gyre Therapeutics reported that China’s National Medical Products Administration has accepted the New Drug Application for F351. This treatment is designed for chronic hepatitis B-induced liver fibrosis. The acceptance follows the administration’s decision to grant priority review status to the drug earlier this year. The application was submitted through Gyre’s majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. This marks the company’s third submission accepted for review by the regulatory body.